Developments in personalized therapy for metastatic renal cell carcinoma.

Fujiwara, Ryo; Kageyama, Susumu; Yuasa, Takeshi

Fujiwara, Ryo; Kageyama, Susumu; Yuasa, Takeshi.

Afiliação

Fujiwara R; Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Kageyama S; Department of Urology, Shiga University of Medical Science, Otsu, Japan.
Yuasa T; Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.

Expert Rev Anticancer Ther ; 22(6): 647-655, 2022 06.

Article em En | MEDLINE | ID: mdl-35531636

Assuntos

Carcinoma de Células Renais; Inibidores de Checkpoint Imunológico; Neoplasias Renais; Axitinibe; Carcinoma de Células Renais/patologia; Humanos; Inibidores de Checkpoint Imunológico/uso terapêutico; Neoplasias Renais/patologia; Nivolumabe/uso terapêutico; Medicina de Precisão

Palavras-chave

Immune checkpoint inhibitor (ICI); avelumab plus axitinib; combination therapy; nivolumab plus cabozantinib; nivolumab plus ipilimumab; pembrolizumab plus axitinib; pembrolizumab plus lenvatinib; tyrosine kinase inhibitor (TKI)

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Inibidores de Checkpoint Imunológico / Neoplasias Renais Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google